To the Editor: At the City of Hope National Medical Center, we have had substantial experience with the use of granulocytes and amphotericin B as part of our bone-marrow transplantation program for hematologic cancers. Our experience is considerably different from that reported by Wright and his co-workers in the May 14 issue.* Between May 1976 and May 1981, 95 patients with hematologic cancer underwent bone-marrow transplantation. The first 77 patients received prophylactic granulocyte support when the white-cell count fell below 500 per microliter, and they continued to receive this support until the count was above 500 per microliter (nine to.
ASJC Scopus subject areas